A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

PHASE2RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

May 28, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
VEXASVEXAS Syndrome
Interventions
DRUG

Pacritinib

Supplied in hard capsules.

DRUG

Placebo

Supplied in hard capsules.

Trial Locations (40)

10016

RECRUITING

NYU Langone Health, New York

20132

RECRUITING

Hospital San Raffaele, IRCCS, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Milan

20246

RECRUITING

University Hospital Hamburg-Eppendorf, Hamburg

21201

NOT_YET_RECRUITING

University of Maryland Medical Center Midtown Campus, Baltimore

23538

RECRUITING

University Hospital Schleswig-Holstein, Lübeck

31100

RECRUITING

IUCT-Oncopole, Toulouse

35128

NOT_YET_RECRUITING

University Hospital of Padova, Rheumatology Unit, Department of Medicine - DIMED, Padua

37007

RECRUITING

University Clinical Hospital of Salamanca, Salamanca

40225

RECRUITING

University Hospital Duesseldorf, Düsseldorf

42123

RECRUITING

AUSL of Reggio Emilia - Hospital Arcispedale S. Maria Nuova, Complex Structure of Rheumatology, Reggio Emilia

43210

RECRUITING

The James Cancer Hospital and Solove Research Institute, Columbus

44195

RECRUITING

Cleveland Clinic - Cleveland, Cleveland

55905

RECRUITING

Mayo Clinic - Rochester, Rochester

59037

RECRUITING

Lille University Hospital Center, Lille

69310

RECRUITING

Hospices Civils de Lyon - Lyon Sud, Pierre-Bénite

72076

RECRUITING

University Hospital Tuebingen, Medical Clinic II, Hematology, Oncology, Clinical Immunology and Rheumatology, Tübingen

75012

RECRUITING

Saint-Antoine Hospital - APHP, Paris

75020

RECRUITING

Tenon Hospital - APHP, Paris

77030

RECRUITING

UT MD Anderson Cancer Center, Houston

81675

RECRUITING

Hospital Rechts der Isar of the Technical University of Munich, Clinic and Polyclinic for Internal Medicine III: Hematology and Internal Oncology, Munich

84132

RECRUITING

University of Utah Healthcare, Salt Lake City

85259

RECRUITING

Mayo Clinic - Scottsdale, Scottsdale

86000

RECRUITING

University Hospital Center of Poitiers, Poitiers

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

02215

RECRUITING

Dana Farber Cancer Institute, Boston

V5Z 1M9

RECRUITING

Vancouver Coastal Health Research Institute, Vancouver

B3H 2Y9

NOT_YET_RECRUITING

Queen Elizabeth II Health Sciences Center, Halifax

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

H4J 1C5

RECRUITING

Hospital du Sacre-Coeur in Montreal, Montreal

01307

RECRUITING

University Hospital Carl Gustav Carus Dresden, Medical Clinic and Polyclinic I, Dresden

00133

RECRUITING

Foundation PTV - Polyclinic Tor Vergata Biomedicine and prevention, Roma

960-1295

RECRUITING

Fukushima Medical University Hospital, Fukushima

852-8501

NOT_YET_RECRUITING

Nagasaki University Hospital, Nagasaki

236-0004

RECRUITING

Yokohama City University Hospital, Yokohama

08036

RECRUITING

Hospital Clinic of Barcelona, Barcelona

08908

RECRUITING

Catalan Institute of Oncology, Hospital Duran i Reynals, Department of Clinical Hematology, L'Hospitalet de Llobregat

LS9 7TF

RECRUITING

St James's University Hospital, Leeds

NW3 2QG

NOT_YET_RECRUITING

Royal Free Hospital, London

SE5 9RS

NOT_YET_RECRUITING

King's College Hospital, Department of Hematology, London

OX3 7LE

NOT_YET_RECRUITING

Churchill Hospital, Oxford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

PSI CRO

INDUSTRY

lead

Swedish Orphan Biovitrum

INDUSTRY